Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,777.90 | 50.80 | -0.58% |
| CAC 40 | 7,878.46 | 111.75 | 1.44% |
| DAX 40 | 24,549.56 | 342.65 | 1.42% |
| Dow JONES (US) | 44,379.04 | 138.28 | 0.31% |
| FTSE 100 | 8,867.02 | 12.84 | 0.15% |
| HKSE | 23,892.32 | 255.75 | -1.06% |
| NASDAQ | 20,549.17 | 130.71 | 0.64% |
| Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
| NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
| S&P 500 | 6,248.37 | 22.85 | 0.37% |
| S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
| SSE Composite Index | 3,493.05 | 4.43 | -0.13% |